Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion.

Saved in:
Bibliographic Details
Title: Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion.
Authors: Villodre ES; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; MD Anderson Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hu X; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; MD Anderson Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Larson R; MD Anderson Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Finetti P; Laboratory of Predictive Oncology, Aix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France., Gomez K; Department of Biological Sciences, The University of Texas at Brownsville, TX, USA., Balema W; MD Anderson Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stecklein SR; MD Anderson Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Santiago-Sanchez G; Department Biochemistry and Cancer Center, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico., Krishnamurthy S; MD Anderson Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Song J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Su X; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ueno NT; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; MD Anderson Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tripathy D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; MD Anderson Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Van Laere S; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Belgium., Bertucci F; Laboratory of Predictive Oncology, Aix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France., Vivas-Mejía P; Department Biochemistry and Cancer Center, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico., Woodward WA; MD Anderson Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Debeb BG; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; MD Anderson Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Source: Molecular oncology [Mol Oncol] 2021 Oct; Vol. 15 (10), pp. 2752-2765. Date of Electronic Publication: 2021 Aug 27.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1878-0261
DOI:10.1002/1878-0261.13074